J
Jose Luiz Pedrini
Publications - 21
Citations - 6768
Jose Luiz Pedrini is an academic researcher. The author has contributed to research in topics: Breast cancer & Pertuzumab. The author has an hindex of 13, co-authored 18 publications receiving 5500 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga,Javier Cortes,Sung-Bae Kim,Seock-Ah Im,Roberto Hegg,Young-Hyuck Im,L Roman,Jose Luiz Pedrini,Tadeusz Pienkowski,Adam Knott,Emma Clark,Mark C. Benyunes,Graham Ross,Sandra M. Swain +13 more
TL;DR: The combination of pertuzumab plus trastuzumAB plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.
Journal ArticleDOI
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more
TL;DR: Pertuzumab and trastuzumAB without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile, which justifies further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer.
Journal ArticleDOI
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni,Urania Dafni,Richard D. Gelber,Evandro de Azambuja,S. Muehlbauer,Aron Goldhirsch,Michael Untch,Ian E. Smith,José Baselga,Christian Jackisch,David Cameron,Max S. Mano,Jose Luiz Pedrini,Andrea Veronesi,Cesar Mendiola,Anna Pluzanska,Vladimir Semiglazov,Eduard Vrdoljak,Michael J Eckart,Zhenzhou Shen,George Skiadopoulos,Marion Procter,Kathleen I. Pritchard,Martine Piccart-Gebhart,Richard Bell +24 more
TL;DR: Treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4-year median follow-up and a substantial selective crossover of patients in the observation group to trastzumab was associated with improved outcomes for this cohort.
Journal ArticleDOI
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Domenico Magazzu,V. McNally,Hannah Douthwaite,G. Ross,G. Ross,Pinuccia Valagussa +20 more
TL;DR: The primary endpoint (pathological complete response) was previously reported and secondary endpoints reported here are 5-year progression-free survival (analysed in the intention-to-treat population) and disease- free survival ( analysed in patients who had surgery).
Journal ArticleDOI
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
Angelo Di Leo,Guy Jerusalem,Lubos Petruzelka,Roberto Torres,Igor Bondarenko,Rustem Khasanov,Didier Verhoeven,Jose Luiz Pedrini,Iya Smirnova,Mikhail Lichinitser,Kelly Pendergrass,Sally Garnett,Justin P.O. Lindemann,Francisco Sapunar,Miguel Martin +14 more
TL;DR: Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.